| Value | ₹62.00 Cr |
|---|
BSE filing, NSE: SENORES. Summary written from the filing by ALFA Finder's alert engine.
Senores Pharmaceuticals Ltd: key numbers
- Share price
- ₹1,201.00
- Market cap
- ₹5,531 Cr
- Revenue (annual)
- ₹632.6 Cr
- Net profit (annual)
- ₹115.4 Cr
- P/E (TTM)
- 41.4×Sector 37.9×
- Promoter holding
- 45.82%+0.00% QoQ
- FII holding
- 6.01%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Senores Pharmaceuticals Ltd
All →Senores Pharmaceuticals Earnings Call Transcript: Key Takeaways
Senores delivered record quarterly revenue and EBITDA, driven by US portfolio expansion and regulated market growth.
- Call
- Guides 40% growth
Senores Pharmaceuticals Other Announcement
Senores Pharmaceuticals reported no deviation in utilising the Rs 95 Crore raised via a preferential warrant issue for the quarter ended September 30, 2026. Audit Committee reviewed the statement and the Board took it on record.
- Value
- ₹95.00 Cr
Senores Pharmaceuticals Capacity Expansion: ₹20 Cr Investment
Senores Pharmaceuticals' subsidiary Apnar Pharma Private Limited plans a 0.7 Bn unit capacity addition by March 2027. The investment is Rs.20.00 Crore, funded by internal accruals and IPO proceeds.
- Value
- ₹20.00 Cr
- Execution
- By end of March 2027
- production capacity
- 0.7 Bn units
Senores Pharmaceuticals Capacity Expansion: ₹18 Cr Investment
Senores Pharmaceuticals plans to add 0.8 Bn units of capacity to its existing 1.2 Bn unit plant by March 2027. The investment is Rs.18.00 Crore, funded by internal accruals and IPO proceeds.
- Value
- ₹18.00 Cr
- Execution
- By end of March 2027
- production capacity
- 0.8 Bn units
Senores Pharmaceuticals Other Announcement
Senores Pharmaceuticals appointed Talati and Talati LLP as Statutory Auditor for a 60-month term, effective 29 October 2026. The appointment was approved at the board meeting held the same day.
- Execution
- 60 months
Senores Pharmaceuticals Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹192.3 Cr (+24.9%), EBITDA ₹57.7 Cr (+38.3%, 30.0% margin), PAT ₹36.6 Cr. H1 revenue +30%, EBITDA +58.2%.
Other debt & borrowing announcements
All →RateGain Travel Technologies Debt & Borrowing: ₹434.8 Cr
RateGain Travel Technologies' UK subsidiary has prepaid USD 46.25 Million (approx. ₹434.75 Crore) of its loan facility. This reduces the outstanding debt to USD 31.25 Million.
- Value
- ₹434.8 Cr
Arman Financial Services Debt & Borrowing: ₹0.23 Cr
Arman Financial Services Limited paid a monthly interest of Rs. 0.23 Crore on its Non-Convertible Debentures. The payment corresponds to ISIN INE109C07105 for an issue size of Rs. 40 Crore.
- Value
- ₹0.23 Cr
Share India Securities Debt & Borrowing: ₹75 Cr
Share India Securities Limited has allotted 75,000 secured non-convertible debentures on a private placement basis. The issue, valued at Rs. 75 Crore, features a face value of Rs. 10,000 per instrument.
- Value
- ₹75.00 Cr
NLC India Debt & Borrowing: ₹2,500 Cr
NLC India Limited's board has approved the issuance of debt securities worth Rs. 2,500 Crore. The securities are proposed to be listed on both BSE and NSE.
- Value
- ₹2,500 Cr
Bhilwara Spinners Debt & Borrowing: ₹450 Cr
Bhilwara Spinners seeks member approval via postal ballot to raise its overall borrowing limit to Rs 450 crore under Section 180(1)(c). E-voting runs 6 Nov to 7 Dec 2026.
- Value
- ₹450.0 Cr
Bhilwara Spinners Debt & Borrowing
Bhilwara Spinners seeks shareholder approval to raise its borrowing limit to Rs.450 Crore via postal ballot. Remote e-voting runs from 5 November to 6 December 2026.